Impact of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol concentrations in individuals with metastatic renal cell carcinoma: a retrospective analysis

1

Cabozantinib (CABO) may induce primary adrenal insufficiency (PAI) in patients with metastatic renal cell carcinoma (mRCC).
2

A retrospective study analyzed plasma adrenocorticotropic hormone (ACTH) and serum cortisol levels in 18 patients treated with CABO.
3

Patients with elevated plasma ACTH levels during CABO treatment exhibited symptoms like fatigue and appetite loss.
4

The study found that regular monitoring of ACTH and cortisol levels is not currently recommended for TKI treatments.
5

The case study highlights the need for further research on TKI-induced adrenal dysfunction and its clinical implications.

Bmc Endocrine Disorders

by Yuji Hataya, Mayuka Kurata, Kimiaki Murabe, Takuro Hakata, Kanta Fujimoto, Toshio Iwakura, Toshinari Yamasaki, Naoki Matsuoka
November 4, 2025

1